Eidos Therapeutics (NASDAQ:EIDX) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Eidos Therapeutics (NASDAQ:EIDX) from a hold rating to a sell rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “

Several other brokerages also recently commented on EIDX. BTIG Research set a $14.00 price objective on ARBOR RLTY TR I/SH and gave the stock a buy rating in a research note on Wednesday, April 17th. BMO Capital Markets downgraded Capital Power from an outperform rating to a market perform rating in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $30.29.

NASDAQ:EIDX opened at $39.97 on Wednesday. Eidos Therapeutics has a 12-month low of $8.89 and a 12-month high of $40.52. The company has a debt-to-equity ratio of 0.01, a current ratio of 19.04 and a quick ratio of 19.04. The company has a market cap of $1.47 billion and a price-to-earnings ratio of -21.49. The business has a fifty day moving average of $31.66.

Eidos Therapeutics (NASDAQ:EIDX) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). On average, sell-side analysts predict that Eidos Therapeutics will post -1.73 earnings per share for the current year.

In other Eidos Therapeutics news, major shareholder Bridgebio Pharma, Inc. acquired 1,103,848 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were acquired at an average price of $25.93 per share, with a total value of $28,622,778.64. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Christine Siu sold 5,000 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $26.11, for a total value of $130,550.00. The disclosure for this sale can be found here. Insiders have sold a total of 62,000 shares of company stock worth $1,820,890 in the last ninety days.

A number of institutional investors have recently modified their holdings of EIDX. New York State Common Retirement Fund acquired a new stake in Eidos Therapeutics during the 4th quarter worth $69,000. BNP Paribas Arbitrage SA acquired a new stake in shares of Eidos Therapeutics in the 1st quarter valued at about $80,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Eidos Therapeutics in the 1st quarter valued at about $143,000. MetLife Investment Advisors LLC acquired a new stake in shares of Eidos Therapeutics in the 1st quarter valued at about $198,000. Finally, Fiduciary Trust Co. acquired a new stake in shares of Eidos Therapeutics in the 1st quarter valued at about $211,000. 34.01% of the stock is currently owned by institutional investors and hedge funds.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Further Reading: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on Eidos Therapeutics (EIDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.